ISIS Pharmaceuticals, Inc. Share Price Nasdaq
Equities
US4643301090
Biotechnology & Medical Research
Sales 2024 * | 620M 51.7B | Sales 2025 * | 777M 64.78B | Capitalization | 6.02B 502B |
---|---|---|---|---|---|
Net income 2024 * | -568M -47.39B | Net income 2025 * | -493M -41.13B | EV / Sales 2024 * | 9.53 x |
Net cash position 2024 * | 111M 9.25B | Net Debt 2025 * | 218M 18.21B | EV / Sales 2025 * | 8.03 x |
P/E ratio 2024 * |
-10.5
x | P/E ratio 2025 * |
-12.4
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.13% |
Latest transcript on ISIS Pharmaceuticals, Inc.
Managers | Title | Age | Since |
---|---|---|---|
D. Walke
FOU | Founder | 58 | 01/12/01 |
Brett Monia
FOU | Founder | 62 | 10/89/10 |
Elizabeth Hougen
DFI | Director of Finance/CFO | 62 | 01/00/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Joseph Loscalzo
CHM | Chairman | 72 | 03/14/03 |
Brett Monia
FOU | Founder | 62 | 10/89/10 |
Joan Herman
BRD | Director/Board Member | 70 | 10/19/10 |
1st Jan change | Capi. | |
---|---|---|
+0.17% | 42.19B | |
+10.92% | 42.24B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+5.23% | 24.63B | |
-24.79% | 18.2B | |
+26.69% | 12.01B | |
-3.13% | 11.76B | |
+6.57% | 10.4B |